|
Frontier IP Group PLC - London-based intellectual property commercialisation firm - Portfolio company Amprologix raises £740,000 to accelerate development of its novel antibiotics for antimicrobial-resistant diseases. Funds will go towards completion of the pre-clinical development of lead candidate epidermicin NI01, which is being developed to treat Methicillin-resistant Staphylococcus aureus, MRSA. Expects phase 1 human clinical trials to start next year. Says Amprologix is also preparing for a Series A funding round. Investors in the recent fundraise included individuals and ‘angel-investor network’ Plutus Investment Group LLP. Plutus’ Venture Partner Rita Dobmeyer will be joining Amprologix’s board as a non-executive director to support clinical development. Frontier says Amprologix is also in the early stages of developing an antibiotic to treat and prevent Clostridioides difficile or C difficile infections. ‘The World Health Organisation has identified antimicrobial-resistant diseases as one of the top 10 threats to human health globally,’ says Frontier Chief Executive Neil Crabb. ‘I am therefore excited by the potential for Amprologix’s novel antibiotics in helping to fight this scourge. Research results to date have been highly encouraging, and I am delighted by the success of this funding round, which will play a vital role in taking epidermicin NI01 through to human clinical trials.’ Current stock price: 18.10 pence 12-month change: down 38% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
